Earnest Partners LLC Raises Stock Holdings in Charles River Laboratories International, Inc. $CRL

Earnest Partners LLC raised its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 0.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,006,724 shares of the medical research company’s stock after buying an additional 8,467 shares during the quarter. Earnest Partners LLC’s holdings in Charles River Laboratories International were worth $157,512,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Banco Bilbao Vizcaya Argentaria S.A. raised its stake in shares of Charles River Laboratories International by 2.8% in the 3rd quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 14,559 shares of the medical research company’s stock valued at $2,278,000 after acquiring an additional 403 shares during the period. Bridgefront Capital LLC purchased a new position in shares of Charles River Laboratories International during the 3rd quarter worth approximately $368,000. Bank of America Corp DE increased its holdings in Charles River Laboratories International by 13.4% in the 3rd quarter. Bank of America Corp DE now owns 1,163,348 shares of the medical research company’s stock valued at $182,017,000 after purchasing an additional 137,335 shares during the last quarter. Algert Global LLC increased its holdings in Charles River Laboratories International by 54.0% in the 3rd quarter. Algert Global LLC now owns 112,870 shares of the medical research company’s stock valued at $17,660,000 after purchasing an additional 39,586 shares during the last quarter. Finally, Alliancebernstein L.P. raised its position in Charles River Laboratories International by 232.8% in the third quarter. Alliancebernstein L.P. now owns 219,975 shares of the medical research company’s stock valued at $34,417,000 after purchasing an additional 153,868 shares during the period. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Stock Performance

Shares of CRL stock opened at $155.61 on Friday. The firm has a 50 day moving average of $191.59 and a two-hundred day moving average of $181.00. The stock has a market capitalization of $7.66 billion, a PE ratio of -52.57, a P/E/G ratio of 2.66 and a beta of 1.64. The company has a quick ratio of 1.02, a current ratio of 1.29 and a debt-to-equity ratio of 0.67. Charles River Laboratories International, Inc. has a 52 week low of $91.86 and a 52 week high of $228.88.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Wednesday, February 18th. The medical research company reported $2.39 earnings per share for the quarter, topping analysts’ consensus estimates of $2.33 by $0.06. The business had revenue of $994.23 million for the quarter, compared to analyst estimates of $986.98 million. Charles River Laboratories International had a positive return on equity of 15.60% and a negative net margin of 3.59%.The company’s revenue was down .8% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.66 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS. On average, research analysts predict that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. Robert W. Baird set a $193.00 price target on Charles River Laboratories International in a research report on Thursday, February 19th. Morgan Stanley set a $185.00 price objective on Charles River Laboratories International in a report on Monday, December 1st. Wall Street Zen lowered Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Saturday, February 21st. Weiss Ratings restated a “sell (d)” rating on shares of Charles River Laboratories International in a report on Wednesday, January 21st. Finally, UBS Group lifted their target price on Charles River Laboratories International from $170.00 to $175.00 and gave the company a “neutral” rating in a research report on Wednesday, February 25th. Ten research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $203.57.

Charles River Laboratories International News Summary

Here are the key news stories impacting Charles River Laboratories International this week:

• Positive Sentiment: Zacks raised its FY2027 EPS view to $11.62 (from $11.30), signaling stronger full‑year outlook and supporting a higher valuation multiple. Zacks FY2027 boost
• Positive Sentiment: Zacks lifted FY2026 EPS to $10.78 (from $10.68), implying near‑term margin or revenue improvement versus prior assumptions. Zacks FY2026 boost
• Positive Sentiment: Zacks published FY2028 EPS of $12.12, reflecting continued expected earnings growth beyond FY2027. Long‑term upgrades can lift investor sentiment. Zacks FY2028 outlook
• Positive Sentiment: Multiple quarterly raises: Q3 2026 to $2.86, Q3 2027 to $3.02, Q4 2026 to $3.02, and Q4 2027 to $3.32 — these sequential upgrades point to improving quarterly momentum. Zacks quarterly upgrades
• Positive Sentiment: Zacks raised mid‑2026 quarterly views (Q2 2026 to $2.85 and Q2/Q3 2026 lifts), indicating expectations for recovery or stronger demand in the upcoming fiscal periods. Zacks mid‑2026 raises
• Neutral Sentiment: Zacks’ estimates differ from the consensus full‑year figure repeatedly cited ($9.36), meaning analyst views remain divergent; the Zacks upgrades imply upside versus consensus but do not change consensus itself. Consensus vs Zacks
• Negative Sentiment: Zacks lowered Q1 2026 EPS from $2.39 to $2.05, a material near‑term cut that could pressure the next quarter’s reported results and short‑term sentiment. Zacks Q1 2026 cut
• Negative Sentiment: Zacks slightly trimmed Q2 2027 to $2.65 (from $2.67), a minor downgrade but another signal of some variability in near‑term cadence. Zacks Q2 2027 trim

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.